Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Sell

C

Affimed N.V. (AFMD)

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/12/2014

Market Cap

61,366,825

Shares Outstanding

149,340,000

Weighted SO

149,339,335

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

TCRR --.--%

PIRS --.--%

ADCT --.--%

AGEN --.--%

XFOR --.--%

TERN --.--%

DAWN --.--%

PDSB --.--%

INZY --.--%

Beta

2.1240

Last Div

0.0000

Range

2.24-8.95

Chg

0.0800

Avg Vol

728719

Mkt Cap

61366825

Exch

NASDAQ

Country

DE

Phone

49 6221 6743 60

DCF Diff

8.2662

DCF

-4.1262

Div Yield

0.0000

P/S

14.2238

EV Multiple

-0.6372

P/FV

1.3624

Div Yield %

0.0000

P/E

-0.5949

PEG

0.0342

Payout

0.0000

Current Ratio

3.0597

Quick Ratio

3.0252

Cash Ratio

0.7063

DSO

562.2117

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

1.0000

Op Margin

-24.1671

Pretax Margin

-23.7577

Net Margin

-23.7577

Eff Tax Rate

-0.0536

ROA

-1.3200

ROE

-1.3605

ROCE

-1.8857

NI/EBT

1.0000

EBT/EBIT

0.9831

EBIT/Rev

-24.1671

Debt Ratio

0.2278

D/E

0.3952

LT Debt/Cap

0.1856

Total Debt/Cap

0.2833

Int Coverage

-55.9900

CF/Debt

-6.2748

Equity Multi

1.7351

Rec Turnover

0.6492

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.4681

Asset Turnover

0.0556

OCF/Share

-6.6651

FCF/Share

-6.9111

Cash/Share

3.2634

OCF/Sales

-25.7253

FCF/OCF

1.0369

CF Coverage

-6.2748

ST Coverage

-14.8190

CapEx Coverage

-27.0938

Div&CapEx Cov

-27.0938

P/BV

1.3624

P/B

1.3624

P/S

14.2238

P/E

-0.5949

P/FCF

-0.5332

P/OCF

-0.5494

P/CF

-0.5494

PEG

0.0342

P/S

14.2238

EV Multiple

-0.6372

P/FV

1.3624

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 01, 17:02 Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort GlobeNewswire Inc. Jan 03, 06:30 Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck GlobeNewswire Inc. Dec 11, 06:02 Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients GlobeNewswire Inc. Dec 04, 06:30 Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24 GlobeNewswire Inc. Nov 14, 06:30 Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress GlobeNewswire Inc. Nov 09, 06:30 Affimed Announces Acimtamig as International Nonproprietary Name for AFM13 GlobeNewswire Inc. Nov 07, 06:30 Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023 GlobeNewswire Inc. Nov 01, 06:30 Affimed to Participate in Upcoming Investor Conferences

Revenue Product Segmentation